van Bruggen

Aug 13, 2024 | link.springer.com | van Bruggen |De Haas |Long-Term Care

AbstractDespite the effect on blood lipid levels, the clinical benefits of intensive versus standard pharmacological lipid-lowering therapy remain unclear. Previous reviews have presented relative effects on the risk of clinical outcomes, but not the absolute risk reductions (ARRs) and the time gained to a clinical outcome, also called outcome postponement (OP).

Jun 21, 2024 | link.springer.com | van Bruggen

AbstractBaseline imbalances have been identified in randomized trials of evolocumab and alirocumab. Our aim was to quantitatively assess (1) the presence of systematic baseline differences, and (2) the relationship of baseline differences with effects on low-density lipoprotein-cholesterol (LDL-c) and clinical outcomes in the trials. We performed a meta-epidemiological study. PubMed, Embase, regulatory reports, ClinicalTrials.gov and company websites were searched for trials.

May 23, 2023 | trialsjournal.biomedcentral.com | Mary Lou |van Bruggen |Diabetes Victoria |Le Gautier

DesignThis study uses a hybrid type I effectiveness-implementation trial design [26] to test the effectiveness of LISTEN in a two-arm pragmatic, individual-level randomised controlled trial (RCT). We will simultaneously gather information on any barriers to, and facilitators of, implementation [26]. LISTEN (intervention) will be compared to usual care (comparison group), in terms of its impact on diabetes distress at 8 weeks (T1) and 6 months (T2) post-randomisation.